Tunable control of B. infantis abundance and gut metabolites by co-administration of human milk oligosaccharides.

ABSTRACT: Precision engineering of the gut microbiome holds promise as an effective therapeutic approach for diseases associated with a disruption in this microbial community. Engrafting a live biotherapeutic product (LBP) in a predictable, controllable manner is key to the consistent success of this approach and has remained a challenge for most LBPs under development. We recently demonstrated high-level engraftment of Bifidobacterium longum subsp. infantis (B. infantis) in adults when co-dosed with a specific prebiotic, human milk oligosaccharides (HMO). Here, we present a cellular kinetic-pharmacodynamic approach, analogous to pharmacokinetic-pharmacodynamic-based analyses of small molecule- and biologic-based drugs, to establish how HMO controls expansion, abundance, and metabolic

SUBMITTER: Reens AL 

PROVIDER: S-EPMC10798361 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature